Time Commitment: 5 hours over 56 days
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Oncology, Radiology, Urology
Credits Available: 5.0 AMA PRA Category 1 Credit™ & 5 MOC points

This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC). Prostate cancer is the most common solid cancer in men worldwide. Most men are diagnosed as having localized disease because of the widespread use of prostate-specific antigen screening. Men diagnosed as having clinically localized prostate cancer have multiple disease management options, including active surveillance, surgery, or radiotherapy. After local therapy, the treatment of early-stage non-metastatic biochemical recurrence (BCR) in hormone-sensitive (or castrate-sensitive) prostate cancer (HSPC) is not clear cut and options are limited. Treatment options also differ based on whether the patient has a low-risk or high-risk prostate cancer.

CME/CE Accreditation Information

Self Study

Live Group Discussions

  • Live Group Discussion 1

    During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC).

  • Live Group Discussion 2

    During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.

Group Tasks

  • Prostate Cancer Group Task: Theo's Case

    This case follows a 68-year-old gentleman who is diagnosed with prostate cancer and, after initial treatment, eventually develops a biochemical recurrence. The group assignments will cover issues ranging from initial treatment to management of biochemic

My Action Plans

  • Your action plan in: non-metastatic hormone-sensitive prostate cancer

    In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with non-metastatic hormone-sensitive prostate cancer.

Interested in becoming a Group Leader?

Experts in the management of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC). Apply Now

Interested in participating in this curriculum? You can join one of the following groups:

Kara Cossis, PA
Director Advanced Practice Providers
Megan Fonteno, PharmD
Sarcoma/Melanoma Clinical Pharmacist
Associate Professor